{
  "first_published_at": "2008-01-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084710", 
  "title": "Long-acting β2 agonists for asthma: review", 
  "tags": "{\"parsed_therapeutic\": [\"respiratory-disease-allergy\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Respiratory disease and allergy\"]}", 
  "_document_number": 302, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "respiratory-disease-allergy"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Long-acting &#946;<sub>2</sub> agonists for asthma: review</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: January 2008</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Long-acting &#946;2 agonists should be prescribed for the treatment of moderate to severe asthma only in conjunction with inhaled corticosteroids. When appropriate, these medicines should be prescribed in a combination inhaler-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Long-acting &#946;<sub>2</sub> agonists should be prescribed for the treatment of moderate to severe asthma only in conjunction with inhaled corticosteroids. When appropriate, these medicines should be prescribed in a combination inhaler<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>The MHRA has reviewed the use of long-acting &#946;<sub>2</sub> agonists (LABA) in the treatment of asthma after concerns raised by the Salmeterol Multicenter Asthma Research Trial (SMART).<cite>Nelson HS, et al. Chest 2006; <strong>129</strong>: 15&ndash;26</cite></p><p>This double-blind randomised placebo-controlled trial recorded more respiratory-related deaths, asthma-related deaths, and combined asthma-related deaths or lifet-hreatening experiences in the salmeterol group than in the placebo group.</p><p>The MHRA has reviewed: the pharmacology of the two currently available LABA&mdash;salmeterol (Serevent) and formoterol (Atimos Modulite&#9660;, Foradil, Oxis), and the combination products Seretide and Symbicort; the current position of research into the &#946;<sub>2</sub> adrenoreceptor genotype; the epidemiology of asthma in relation to the introduction of LABA; and an overall assessment of the benefits and risks of LABA in the treatment of asthma.</p><p>The conclusions from the review are:</p><ul>\r\n\t\t\t<li>Epidemiological data show that since the introduction of LABA, there has been a decrease in asthma-related hospitalisations in adolescents and a decrease in asthma-related mortality in all ages<br>\r\n\t\t\t\t<br></li>\r\n\t\t\t<li>Data from randomised controlled clinical trials do not suggest a similar safety concern to that shown in postmarketing studies, probably because of moreconsistent use of concomitant inhaled corticosteroids in randomised controlled settings. The data support the use of LABA in conjunction with inhaled corticosteroids in the treatment of moderate to severe asthma consistent with the guideline on the management of asthma from the British Thoracic Society and Scottish Intercollegiate Guidelines Network<br>\r\n\t\t\t\t<br></li>\r\n\t\t\t<li>To aid compliance with the concomitant use of inhaled corticosteroids and LABA, a combination inhaler should be used when appropriate</li></ul><p>Further epidemiological studies are under way to assess the relation between adverse outcomes and use of LABA, the results of which are expected before the end of 2008. The MHRA is also reviewing of the role of LABA in the treatment of asthma in children younger than age 12 years.</p><p>Further information about <a href=\"http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Asthma/index.htm\" target=\"_blank\">LABA in asthma management</a> is available on our website.</p><p>Guidelines on&nbsp;management of asthma: <a href=\"http://www.brit-thoracic.org.uk/clinical-information/asthma/asthma-guidelines.aspx\" target=\"_blank\">British Thoracic Society</a> and&nbsp;<a href=\"http://www.sign.ac.uk/guidelines/fulltext/101/index.html\" target=\"_blank\">The Scottish Intercollegiate Guidelines Network&nbsp;(SIGN)</a>&nbsp;</p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Jan 2008; Vol 1, Issue 6: 9</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>The MHRA has reviewed the use of long-acting &#946;<sub>2</sub> agonists (LABA) in the treatment of asthma after concerns raised by the Salmeterol Multicenter Asthma Research Trial (SMART).<cite>Nelson HS, et al. Chest 2006; <strong>129</strong>: 15&#8211;26</cite></p><p>This double-blind randomised placebo-controlled trial recorded more respiratory-related deaths, asthma-related deaths, and combined asthma-related deaths or lifet-hreatening experiences in the salmeterol group than in the placebo group.</p><p>The MHRA has reviewed: the pharmacology of the two currently available LABA&#8212;salmeterol (Serevent) and formoterol (Atimos Modulite&#9660;, Foradil, Oxis), and the combination products Seretide and Symbicort; the current position of research into the &#946;<sub>2</sub> adrenoreceptor genotype; the epidemiology of asthma in relation to the introduction of LABA; and an overall assessment of the benefits and risks of LABA in the treatment of asthma.</p><p>The conclusions from the review are:</p><ul>\r\n\t\t\t<li>Epidemiological data show that since the introduction of LABA, there has been a decrease in asthma-related hospitalisations in adolescents and a decrease in asthma-related mortality in all ages<br>\r\n\t\t\t\t<br></li>\r\n\t\t\t<li>Data from randomised controlled clinical trials do not suggest a similar safety concern to that shown in postmarketing studies, probably because of moreconsistent use of concomitant inhaled corticosteroids in randomised controlled settings. The data support the use of LABA in conjunction with inhaled corticosteroids in the treatment of moderate to severe asthma consistent with the guideline on the management of asthma from the British Thoracic Society and Scottish Intercollegiate Guidelines Network<br>\r\n\t\t\t\t<br></li>\r\n\t\t\t<li>To aid compliance with the concomitant use of inhaled corticosteroids and LABA, a combination inhaler should be used when appropriate</li></ul><p>Further epidemiological studies are under way to assess the relation between adverse outcomes and use of LABA, the results of which are expected before the end of 2008. The MHRA is also reviewing of the role of LABA in the treatment of asthma in children younger than age 12 years.</p><p>Further information about <a href=\"http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Asthma/index.htm\" target=\"_blank\">LABA in asthma management</a> is available on our website.</p><p>Guidelines on&#160;management of asthma: <a href=\"http://www.brit-thoracic.org.uk/clinical-information/asthma/asthma-guidelines.aspx\" target=\"_blank\">British Thoracic Society</a> and&#160;<a href=\"http://www.sign.ac.uk/guidelines/fulltext/101/index.html\" target=\"_blank\">The Scottish Intercollegiate Guidelines Network&#160;(SIGN)</a>&#160;</p><p>&#160;</p><p><em>Article citation: Drug Safety Update Jan 2008; Vol 1, Issue 6: 9</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2008-01-01", 
  "date_last_modified": "2011-02-10", 
  "_assets": [], 
  "_item_id": 302, 
  "summary": "Long-acting β2 agonists should be prescribed for the treatment of moderate to severe asthma only in conjunction with inhaled corticosteroids. When appropriate, these medicines should be prescribed in a combination inhaler", 
  "body": "Article date: January 2008\n\nThe MHRA has reviewed the use of long-acting β2 agonists (LABA) in the treatment of asthma after concerns raised by the Salmeterol Multicenter Asthma Research Trial (SMART).[^1]\n\nThis double-blind randomised placebo-controlled trial recorded more respiratory-related deaths, asthma-related deaths, and combined asthma-related deaths or lifet-hreatening experiences in the salmeterol group than in the placebo group.\n\nThe MHRA has reviewed: the pharmacology of the two currently available LABA—salmeterol (Serevent) and formoterol (Atimos Modulite▼, Foradil, Oxis), and the combination products Seretide and Symbicort; the current position of research into the β2 adrenoreceptor genotype; the epidemiology of asthma in relation to the introduction of LABA; and an overall assessment of the benefits and risks of LABA in the treatment of asthma.\n\nThe conclusions from the review are:  \n  \n  * Epidemiological data show that since the introduction of LABA, there has been a decrease in asthma-related hospitalisations in adolescents and a decrease in asthma-related mortality in all ages  \n  \n  \n  * Data from randomised controlled clinical trials do not suggest a similar safety concern to that shown in postmarketing studies, probably because of moreconsistent use of concomitant inhaled corticosteroids in randomised controlled settings. The data support the use of LABA in conjunction with inhaled corticosteroids in the treatment of moderate to severe asthma consistent with the guideline on the management of asthma from the British Thoracic Society and Scottish Intercollegiate Guidelines Network  \n  \n  \n  * To aid compliance with the concomitant use of inhaled corticosteroids and LABA, a combination inhaler should be used when appropriate  \n  \nFurther epidemiological studies are under way to assess the relation between adverse outcomes and use of LABA, the results of which are expected before the end of 2008. The MHRA is also reviewing of the role of LABA in the treatment of asthma in children younger than age 12 years.\n\nFurther information about [LABA in asthma management](http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Asthma/index.htm) is available on our website.\n\nGuidelines on management of asthma: [British Thoracic Society](http://www.brit-thoracic.org.uk/clinical-information/asthma/asthma-guidelines.aspx) and [The Scottish Intercollegiate Guidelines Network (SIGN)](http://www.sign.ac.uk/guidelines/fulltext/101/index.html) \n\n \n\nArticle citation: Drug Safety Update Jan 2008; Vol 1, Issue 6: 9\n\n[^1]: Nelson HS, et al. Chest 2006; 129: 15–26\n"
}